Form 4 for DMAC DiaMedica Therapeutics Inc.
Accepted 2023-06-26 00:00:00 ET · period of report 2023-06-23 · accession 0001235802-23-000072 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-26 | 2023-06-23 | DMAC | Pauls Dietrich John | Pres, CEO, Dir | P - Purchase | $3.91 | +12.8K | 68.6K | +23% | +$50.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Shares, no par value per share | 2023-06-23 | P | A | 12,787 | $3.91 | 68,591 | D | — | — | (F1) Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. |